Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE).
Relbo Authen A, Grov I, Karason K, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Dellgren G, Solbu D, Arora S, Andreassen AK, Gullestad L. Relbo Authen A, et al. Among authors: jansson k. Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13038. Epub 2017 Jul 19. Clin Transplant. 2017. PMID: 28640529 Clinical Trial.
Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH. Gullestad L, et al. Among authors: jansson k. Transplantation. 2010 Apr 15;89(7):864-72. doi: 10.1097/TP.0b013e3181cbac2d. Transplantation. 2010. PMID: 20061999 Clinical Trial.
Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial.
Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Iversen M. Gullestad L, et al. Among authors: jansson k. Transplantation. 2010 Dec 27;90(12):1581-9. doi: 10.1097/TP.0b013e3181fd01b7. Transplantation. 2010. PMID: 21030905 Clinical Trial.
Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L. Arora S, et al. Among authors: jansson k. Transplantation. 2011 Jul 27;92(2):235-43. doi: 10.1097/TP.0b013e31822057f1. Transplantation. 2011. PMID: 21677600 Clinical Trial.
Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
Arora S, Gude E, Sigurdardottir V, Mortensen SA, Eiskjær H, Riise G, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Aukrust P, Solbu D, Iversen M, Gullestad L. Arora S, et al. Among authors: jansson k. J Heart Lung Transplant. 2012 Mar;31(3):259-65. doi: 10.1016/j.healun.2011.12.010. J Heart Lung Transplant. 2012. PMID: 22333403 Clinical Trial.
Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial.
Gullestad L, Eiskjaer H, Gustafsson F, Riise GC, Karason K, Dellgren G, Rådegran G, Hansson L, Gude E, Bjørtuft Ø, Jansson K, Schultz HH, Solbu D, Iversen M. Gullestad L, et al. Among authors: jansson k. Transpl Int. 2016 Jul;29(7):819-29. doi: 10.1111/tri.12783. Epub 2016 May 30. Transpl Int. 2016. PMID: 27067532 Free article. Clinical Trial.
Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L; SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*. Gustafsson F, et al. Among authors: jansson k. Transplantation. 2020 Jan;104(1):154-164. doi: 10.1097/TP.0000000000002702. Transplantation. 2020. PMID: 30893292 Clinical Trial.
Predicting mortality during long-term follow-up in pulmonary arterial hypertension.
Kylhammar D, Hjalmarsson C, Hesselstrand R, Jansson K, Kavianipour M, Kjellström B, Nisell M, Söderberg S, Rådegran G. Kylhammar D, et al. Among authors: jansson k. ERJ Open Res. 2021 May 31;7(2):00837-2020. doi: 10.1183/23120541.00837-2020. eCollection 2021 Apr. ERJ Open Res. 2021. PMID: 34084789 Free PMC article.
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study.
Hjalmarsson C, Butler O, Hesselstrand R, Holl K, Jansson K, Klok R, Rådegran G, Söderberg S, Kjellström B. Hjalmarsson C, et al. Among authors: jansson k. Pulm Circ. 2020 Sep 28;10(3):2045894020958557. doi: 10.1177/2045894020958557. eCollection 2020 Jul-Sep. Pulm Circ. 2020. PMID: 33062261 Free PMC article.
278 results